SABA Reliance in Asthma: Revisiting the Window of Opportunity
Industry Webcast Sponsored by AstraZeneca; Not for CME/CE Credit
Short-acting B2-agonists (SABA) have been the mainstay of rescue therapy in asthma, regardless of disease severity. However, we must ask ourselves: at what point does SABA use indicate poor asthma control, and can we do more to prevent exacerbations and oral corticosteroid exposure? This program will examine the relationship between SABA reliance, disease control, and patient behavior and review real world evidence updates to highlight a window of opportunity to prevent exacerbations.
This content is developed exclusively by or on behalf of the industry sponsor; it is not reviewed or associated with Pri-Med and Pri-Med does not endorse or sanction any third-party content.